Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis

Clinical Rheumatology

Volumn 34, Issue 7, 2015, Pages 1289-1292

  Roshique, Kuttipurath Kandi ^a   Ravindran, Vinod ^a  

^a National Hospital   (India)

Author keywords

DMARDs; Innovator biologic; Low disease activity; Remission

Indexed keywords

METHOTREXATE; PREDNISOLONE; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; BIOSIMILAR AGENT;

ACTIVE RHEUMATOID ARTHRITIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INFUSION RELATED REACTION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; MALE; PERIPHERAL NEUROPATHY; PERONEUS NERVE PARALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOID VASCULITIS; TREATMENT DURATION; TREATMENT RESPONSE; ARTHRITIS, RHEUMATOID; MIDDLE AGED; QUESTIONNAIRE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; BLOOD SEDIMENTATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; RITUXIMAB; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 84931562487     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-015-2980-4     Document Type: Article

References (22)

1. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al (2006) DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose ranging trial. Arthritis Rheum 54:1390–1400
2. Cohen SB, Emery P, Greenwald MW et al (2006) REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806
3. Edwards JC, Szczepanski L, Szechinski J et al (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572–2581
4. Rubbert-Roth A, Tak PP, Zerbini C et al (2010) MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683–1693
5. Emery P, Deodhar A, Rigby WF et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE). Ann Rheum Dis 69:1629–1635
6. Tak PP, Rigby W, Rubbert-Roth A et al (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351–357
7. Keystone EJ, Cohen SB, Emery P et al (2012) Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study. J Rheumatol 39:2238–2246
8. De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R, MIRA Study Group (2014) Long-term follow-up of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in rheumatoid arthritis registry. J Rheumatol 41:1761–1765
9. Vital EM, Kay J, Emery P (2013) Rituximab biosimilars. Expert Opin Biol Ther 13:1049–1062
10. Beck A, Reichert JM (2013) Approval of the first biosimilar antibodies in Europe: a major landmark for the biopharmaceutical industry. MAbs 5:621–623
11. World Health Organization (2009) Guidelines on evaluation of similar biotherapeutic products(SBPs).http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed 10 January 2015)
12. Roy PS, John S, Karankal S et al (2013) Comparison of the efficacy and safety of Rituximab (Mabthera™) and its biosimilar (Reditux™) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol 34:292–298
13. Rawat R, Kapoor S, Garg S et al (2009) Efficacy and safety of a biosimilar-rituximab (Reditux™) in rheumatoid arthritis. Indian J Rheumatol 4(Suppl 1):S18–S19
14. Prevoo ML, van’t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48
15. Kumar A, Malaviya AN, Pandhi A, Singh R (2002) Validation of an Indian version of the health assessment questionnaire in patients with rheumatoid arthritis. Rheumatology (Oxford) 41:1457–1459
16. Dörner T, Strand V, Castañeda-Hernández G et al (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322–328
17. Scheinberg MA, Azevedo VF (2014) Biosimilars in rheumatology: perspective and concerns. Rheumatology (Oxford) 53:389–390
18. Park W, Hrycaj P, Jeka S et al (2013) A randomised, double-blind, multicenter, parallel-group, prospective study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 72:1605–1612
19. Dae Hyun Yoo DH, Hrycaj P, Miranda P et al (2013) A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 72:1613–1620
20. Schneider CK (2013) Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72:315–318
21. Jani M, Hirani N, Matteson EL, Dixon WG (2014) The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 10:284–294
22. Maher LV, Wilson JG (2006) Successful treatment of rheumatoid vasculitis-associated foot drop with rituximab. Rheumatology (Oxford) 45:1450–1451